Enter a player name to begin or load your saved progress.
The CoviVac vaccine was developed by the Chumakov Centre, an institution affiliated with the Russian Academy of Sciences.
Answer: True
Explanation: The Chumakov Centre, a significant national research institution under the Russian Academy of Sciences, is credited with the development of the CoviVac vaccine.
The Chumakov Centre's affiliation with the Russian Academy of Sciences indicates its status as a significant national research institution.
Answer: True
Explanation: The affiliation of the Chumakov Centre with the Russian Academy of Sciences underscores its role as a major national scientific research body, lending credibility to its vaccine development efforts.
Which institution developed the CoviVac vaccine?
Answer: Chumakov Centre
Explanation: The CoviVac vaccine was developed by the Chumakov Centre, which is part of the Russian Academy of Sciences.
CoviVac is designed to protect against which specific virus?
Answer: SARS-CoV-2
Explanation: CoviVac is specifically designed to provide protection against SARS-CoV-2, the virus responsible for COVID-19.
Which of the following statements accurately describes CoviVac's development context?
Answer: It was developed in Russia by the Chumakov Centre.
Explanation: CoviVac was developed in Russia by the Chumakov Centre, utilizing inactivated virus technology.
CoviVac is a vaccine developed in Russia that utilizes inactivated virus technology.
Answer: True
Explanation: CoviVac employs an inactivated virus-based technology, meaning it uses a chemically treated, non-infectious form of the SARS-CoV-2 virus to stimulate an immune response.
Beta-propiolactone is used in CoviVac to enhance the immune response.
Answer: False
Explanation: Beta-propiolactone is used in the CoviVac manufacturing process to inactivate the virus, not to enhance the immune response. Aluminum hydroxide serves as the adjuvant for immune enhancement.
CoviVac's manufacturing process is based on mRNA technology, similar to some Western vaccines.
Answer: False
Explanation: CoviVac utilizes traditional inactivated virus-based technology, which is distinct from mRNA technology employed by some Western vaccines. Its process is similar to that of the inactivated polio vaccine.
Vero cells are used in CoviVac production to inactivate the virus.
Answer: False
Explanation: Vero cells are used in CoviVac production to cultivate the SARS-CoV-2 virus. Beta-propiolactone is the chemical agent used to inactivate the virus.
CoviVac uses a live, attenuated version of the SARS-CoV-2 virus.
Answer: False
Explanation: CoviVac is an inactivated virus vaccine, meaning it uses killed virus particles, not a live, attenuated version.
CoviVac is classified as a viral vector vaccine.
Answer: False
Explanation: CoviVac is classified as an inactivated virus-based vaccine, not a viral vector vaccine.
The vaccine's manufacturing process is similar to that used for the inactivated polio vaccine.
Answer: True
Explanation: CoviVac's manufacturing process employs a traditional inactivated vaccine technology, which is comparable to the methods historically used for producing the inactivated polio vaccine.
What type of vaccine technology does CoviVac utilize?
Answer: Inactivated virus-based technology
Explanation: CoviVac is based on inactivated virus technology, meaning it uses killed virus particles to elicit an immune response.
Which chemical agent is used to inactivate the virus in CoviVac?
Answer: Beta-propiolactone
Explanation: Beta-propiolactone is employed in the CoviVac manufacturing process to inactivate the SARS-CoV-2 virus.
How does CoviVac's manufacturing technology compare to other established methods?
Answer: It is based on the same traditional inactivated vaccine technology as the polio vaccine.
Explanation: CoviVac's manufacturing process utilizes traditional inactivated vaccine technology, similar to that used for the inactivated polio vaccine.
What role do Vero cells play in the CoviVac production process?
Answer: They are used to cultivate the SARS-CoV-2 virus.
Explanation: Vero cells are utilized in the CoviVac production process for the cultivation of the SARS-CoV-2 virus, which is subsequently inactivated.
What is the function of beta-propiolactone in the CoviVac manufacturing process?
Answer: To render the virus non-infectious.
Explanation: Beta-propiolactone is used in the CoviVac manufacturing process to chemically inactivate the virus, rendering it non-infectious while preserving its antigenic structure.
The CoviVac vaccine manufacturing process is described as similar to the production method for which other vaccine?
Answer: The inactivated polio vaccine
Explanation: The manufacturing process for CoviVac is similar to the traditional method used for producing the inactivated polio vaccine.
What does the term 'inactivated virus-based vaccine' mean in the context of CoviVac?
Answer: The vaccine uses virus particles that have been killed and cannot cause infection.
Explanation: An inactivated virus-based vaccine, like CoviVac, contains virus particles that have been rendered non-infectious through chemical or physical means, while still being capable of eliciting an immune response.
Each dose of CoviVac contains at least 3 micrograms of the SARS-CoV-2 strain AYDAR-1 antigen.
Answer: True
Explanation: A minimum of 3 micrograms of the SARS-CoV-2 strain AYDAR-1 antigen is present in each dose of the CoviVac vaccine.
Aluminum hydroxide is included in CoviVac as an adjuvant to boost immunogenicity.
Answer: True
Explanation: Aluminum hydroxide is utilized in the CoviVac formulation as an adjuvant, which functions to enhance the body's immune response to the vaccine's antigen.
CoviVac is formulated with a phosphate buffer solution containing potassium chloride.
Answer: False
Explanation: The phosphate buffer solution in CoviVac contains disodium phosphate dihydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, and water for injection; potassium chloride is not listed as a component.
An adjuvant's role is to directly kill the virus particles within a vaccine.
Answer: False
Explanation: An adjuvant's function is to enhance the immune response to the vaccine's antigen, not to directly kill virus particles. That role is performed by inactivating agents like beta-propiolactone.
The CoviVac vaccine contains a minimum of 3 µg of antigen per dose.
Answer: True
Explanation: Each dose of CoviVac is formulated to contain a minimum of 3 micrograms (µg) of the SARS-CoV-2 antigen.
Beta-propiolactone is the adjuvant used in CoviVac.
Answer: False
Explanation: Beta-propiolactone is used to inactivate the virus. Aluminum hydroxide serves as the adjuvant in the CoviVac formulation.
What is the minimum amount of SARS-CoV-2 antigen per dose in CoviVac?
Answer: 3 micrograms
Explanation: Each dose of CoviVac contains a minimum of 3 micrograms (µg) of the SARS-CoV-2 strain AYDAR-1 antigen.
What substance serves as an adjuvant in the CoviVac vaccine formulation?
Answer: Aluminum hydroxide
Explanation: Aluminum hydroxide is incorporated into the CoviVac formulation to function as an adjuvant, enhancing the immune response.
Which of the following components is part of CoviVac's phosphate buffer solution?
Answer: Sodium chloride
Explanation: Sodium chloride is one of the components listed in CoviVac's phosphate buffer solution.
What is the purpose of an adjuvant, such as aluminum hydroxide, in the CoviVac vaccine?
Answer: To enhance the immune response to the antigen.
Explanation: Adjuvants like aluminum hydroxide are included in vaccines to stimulate and strengthen the immune system's response to the administered antigen.
Which of the following components is NOT listed as a component of CoviVac's phosphate buffer solution?
Answer: Potassium phosphate
Explanation: Potassium phosphate is not listed among the components of CoviVac's phosphate buffer solution, which includes disodium phosphate dihydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, and water for injection.
CoviVac contains a minimum of 3 µg of which specific SARS-CoV-2 strain antigen?
Answer: AYDAR-1
Explanation: CoviVac contains a minimum of 3 micrograms (µg) of the SARS-CoV-2 strain designated AYDAR-1.
What is the approximate amount of aluminum hydroxide adjuvant per dose in CoviVac?
Answer: 0.3-0.5 mg
Explanation: Each dose of CoviVac contains approximately 0.3 to 0.5 milligrams (mg) of aluminum hydroxide adjuvant.
Which component acts as the adjuvant in CoviVac?
Answer: Aluminum hydroxide
Explanation: Aluminum hydroxide serves as the adjuvant in the CoviVac vaccine formulation, designed to enhance the immune response.
How much antigen is contained in a single dose of CoviVac?
Answer: A minimum of 3 micrograms
Explanation: A single dose of CoviVac contains a minimum of 3 micrograms (µg) of the SARS-CoV-2 strain AYDAR-1 antigen.
CoviVac received official approval for use in Russia on January 20, 2021.
Answer: False
Explanation: CoviVac was officially approved for use in Russia on February 20, 2021, not January 20, 2021.
CoviVac was the second COVID-19 vaccine approved for use in Russia.
Answer: False
Explanation: CoviVac was the third COVID-19 vaccine approved for use in Russia, following Sputnik V and EpiVacCorona.
As of January 2023, CoviVac's efficacy had been confirmed through large-scale Phase III clinical trials.
Answer: False
Explanation: According to the provided information, as of January 2023, the efficacy of CoviVac had not yet been established through a completed Phase III clinical trial.
The initial Phase I/II clinical trials for CoviVac began in September 2020.
Answer: True
Explanation: The Phase I/II clinical trials for CoviVac commenced on September 21, 2020.
The Phase III trials for CoviVac were projected to finish by the end of 2021.
Answer: False
Explanation: The Phase III trials for CoviVac were projected to conclude by December 30, 2022, not the end of 2021.
Permission for Phase III trials is granted only after a vaccine has demonstrated full efficacy in humans.
Answer: False
Explanation: Permission for Phase III trials is granted after a vaccine has demonstrated preliminary safety and immunogenicity in earlier phases, not necessarily full efficacy.
CoviVac's Phase III trials were scheduled to conclude by the end of 2022.
Answer: True
Explanation: The Phase III clinical trials for CoviVac were projected to be completed by December 30, 2022.
CoviVac was approved in Russia before its Phase I/II trials were completed.
Answer: False
Explanation: CoviVac's Phase I/II trials began in September 2020 and were projected to conclude by October 15, 2020. It was approved on February 20, 2021, well after the completion of these initial trials.
When was CoviVac officially approved for use in Russia?
Answer: February 20, 2021
Explanation: CoviVac received its official approval for use in Russia on February 20, 2021.
What was CoviVac's rank among COVID-19 vaccines approved in Russia?
Answer: The third approved vaccine
Explanation: CoviVac was the third COVID-19 vaccine to receive official approval for use in Russia.
According to the source (as of January 2023), what was the status of CoviVac's Phase III clinical trial efficacy?
Answer: Efficacy had not yet been established in a Phase III trial.
Explanation: As of January 2023, the efficacy of CoviVac had not been definitively established through a completed Phase III clinical trial.
When did the Phase I/II clinical trials for CoviVac commence?
Answer: September 21, 2020
Explanation: The initial Phase I/II clinical trials for CoviVac commenced on September 21, 2020.
What was the projected completion date for CoviVac's Phase III clinical trials?
Answer: December 30, 2022
Explanation: The Phase III clinical trials for CoviVac were projected to be completed by December 30, 2022.
The Phase III clinical trials for CoviVac began in which timeframe?
Answer: Early 2021
Explanation: The Phase III clinical trials for CoviVac commenced in early 2021.
Which statement best describes the CoviVac vaccine's status regarding Phase III trials as of January 2023?
Answer: Phase III trials were ongoing, but efficacy was not yet confirmed.
Explanation: As of January 2023, CoviVac's Phase III trials were still ongoing, and its efficacy had not yet been confirmed.
CoviVac was approved in Russia approximately how long after its Phase I/II trials began?
Answer: 5 months
Explanation: CoviVac's Phase I/II trials began in September 2020, and it was approved in February 2021, approximately 5 months later.
What was the projected end date for CoviVac's Phase I/II trials?
Answer: October 15, 2020
Explanation: The initial Phase I/II trials for CoviVac were projected to conclude by October 15, 2020.
What is the significance of CoviVac being the third vaccine approved in Russia?
Answer: It places it chronologically after two other Russian COVID-19 vaccines.
Explanation: CoviVac's status as the third approved vaccine in Russia indicates its chronological placement after Sputnik V and EpiVacCorona.
The CoviVac vaccine requires a single intramuscular injection for full immunization.
Answer: False
Explanation: CoviVac is administered in a two-dose regimen, with a 14-day interval between doses, and is given via intramuscular injection.
CoviVac must be stored at room temperature, between 20-25 degrees Celsius.
Answer: False
Explanation: CoviVac requires storage and transportation at standard refrigerated temperatures, specifically between 2 and 8 degrees Celsius (35.6 to 46.4 degrees Fahrenheit).
A single dose of CoviVac has a volume of 1 milliliter (ml).
Answer: False
Explanation: The volume of a single dose of the CoviVac vaccine is 0.5 milliliters (ml).
Standard refrigeration temperatures range from 2 to 8 degrees Celsius (35.6 to 46.4 degrees Fahrenheit).
Answer: True
Explanation: The standard temperature range for refrigeration, crucial for vaccine storage, is indeed 2 to 8 degrees Celsius, which corresponds to 35.6 to 46.4 degrees Fahrenheit.
CoviVac is administered via an oral route.
Answer: False
Explanation: CoviVac is administered via intramuscular injection, not orally.
The vaccine is stored at temperatures between 2 and 8 degrees Fahrenheit.
Answer: False
Explanation: CoviVac requires storage between 2 and 8 degrees Celsius, which is equivalent to 35.6 to 46.4 degrees Fahrenheit, not simply 2 to 8 degrees Fahrenheit.
CoviVac is administered in a single dose regimen.
Answer: False
Explanation: CoviVac is administered in a two-dose regimen, not a single dose.
How many doses are recommended for the CoviVac vaccine, and what is the interval?
Answer: Two doses, with a 14-day interval
Explanation: The recommended administration schedule for CoviVac consists of two doses, with a 14-day interval between them.
What temperature range is required for storing and transporting CoviVac?
Answer: 2 to 8 degrees Celsius
Explanation: CoviVac must be stored and transported within the standard refrigerated temperature range of 2 to 8 degrees Celsius.
What is the volume of a single dose of the CoviVac vaccine?
Answer: 0.5 ml
Explanation: A single dose of the CoviVac vaccine has a volume of 0.5 milliliters (ml).
The CoviVac vaccine is administered via which route?
Answer: Intramuscular injection
Explanation: The CoviVac vaccine is administered through intramuscular injection.
Which of the following is a correct statement about CoviVac's storage requirements?
Answer: It must be kept at standard refrigerated temperatures (2-8°C).
Explanation: CoviVac requires storage within the standard refrigerated temperature range of 2 to 8 degrees Celsius to maintain its stability and efficacy.
The CAS Number for CoviVac is 1234567-89-0.
Answer: False
Explanation: The correct CAS Number assigned to CoviVac is 2714563-97-8.
The Russian name for CoviVac is Sputnik V.
Answer: False
Explanation: The Russian name for CoviVac is Komivak (Комивак).
CoviVac has been assigned an ATC code for classification purposes.
Answer: False
Explanation: According to the provided information, CoviVac has not been assigned an ATC (Anatomical Therapeutic Chemical) code.
A CAS Number uniquely identifies a specific vaccine formulation, including its adjuvant and buffer components.
Answer: False
Explanation: A CAS Number primarily serves as a unique identifier for a specific chemical substance or compound, such as the CoviVac vaccine itself, rather than detailing its entire formulation including specific adjuvant and buffer components.
Strain AYDAR-1 refers to the specific chemical inactivating agent used in CoviVac.
Answer: False
Explanation: Strain AYDAR-1 refers to the specific isolate of the SARS-CoV-2 virus used in CoviVac's production. Beta-propiolactone is the chemical agent used for inactivation.
The hatnote in the article helps differentiate CoviVac from other potential meanings of 'Covivac'.
Answer: True
Explanation: A hatnote is a navigational aid used to distinguish the subject of an article from other similarly named topics, directing readers to disambiguation pages if necessary.
The description 'pharmaceutical compound' suggests CoviVac is intended for industrial chemical use rather than medical application.
Answer: False
Explanation: The term 'pharmaceutical compound' indicates that CoviVac is intended for medical use, specifically as a vaccine for disease prevention, not for industrial applications.
The vaccine uses the SARS-CoV-2 strain designated AYDAR-1.
Answer: True
Explanation: The specific SARS-CoV-2 strain used in the development and production of CoviVac is designated AYDAR-1.
What is the CAS Number assigned to CoviVac?
Answer: 2714563-97-8
Explanation: The Chemical Abstracts Service (CAS) Number assigned to CoviVac is 2714563-97-8.
What is the Russian name provided for the CoviVac vaccine?
Answer: Komivak
Explanation: The Russian name for the CoviVac vaccine is Komivak (Комивак).
What does the CAS Number 2714563-97-8 uniquely identify according to the source?
Answer: The CoviVac vaccine substance
Explanation: The CAS Number 2714563-97-8 serves as a unique identifier for the CoviVac vaccine substance.
What does the description 'pharmaceutical compound' imply about CoviVac?
Answer: It is a substance intended for medical use, like a vaccine.
Explanation: The designation 'pharmaceutical compound' signifies that CoviVac is a substance intended for medical application, specifically for the prevention of disease as a vaccine.
What is the purpose of the CAS Number 2714563-97-8?
Answer: To serve as a unique identifier for the CoviVac substance.
Explanation: The CAS Number 2714563-97-8 functions as a unique identifier for the CoviVac substance.